CPIX CUMBERLAND PHARMACEUTICALS INC
Price Chart
Executive Summary
Cumberland Pharmaceuticals is seeking shareholder approval to sell its FDA-approved commercial product portfolio (Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ, and Talicia equity interests) to an affiliate of Apotex Inc. for $100 million in cash at closing. The company will retain its ifetroban clinical-stage pipeline and CET subsidiary. The board unanimously recommends approval, and insiders holding ~41% of shares have already committed to vote in favor via support agreements. The special meeting is scheduled for June 24, 2026.
Key Financial Metrics
Actionable Insight
The deal is highly likely to close given insider support (41% committed) and simple majority vote threshold. The $100M cash consideration (~$6.68/share) represents a significant premium to the ~$3.75 pre-announcement price. Post-closing, Cumberland becomes a development-stage biotech with ifetroban pipeline — a binary-risk profile. Traders should monitor the June 24 vote; any delay or shareholder opposition would be a negative surprise. The retained ifetroban DMD program has Fast Track designation and positive Phase 2 data, providing optionality.
Key Facts
- Apotex will pay $100 million in cash at closing for Cumberland's FDA-approved commercial product assets and Talicia equity interests.
- Cumberland retains its ifetroban product candidates (DMD, SSc, IPF programs) and CET subsidiary.
- Insiders holding ~41% of outstanding shares have signed voting and support agreements to vote in favor.
- Board of directors unanimously recommends approval; VelocityHealth Securities issued fairness opinion.
- No appraisal rights for shareholders under Tennessee law.
- Simple majority of outstanding shares (7,491,554 of 14,983,107) required for approval; abstentions and broker non-votes count as votes against.
- Termination fee of $4 million payable by Cumberland under certain conditions (e.g., superior proposal, board recommendation change).
- Apotex has agreed to pay up to $10 million in milestone payments related to Vibativ government contract and net sales.
- Pro forma balance sheet shows estimated gain on sale of ~$63 million after transaction costs and taxes.
- Special meeting scheduled for June 24, 2026; expected closing in Q2 or Q3 2026.
Financial Impact
$100 million cash consideration at closing, representing ~$6.68 per share based on 14.96M shares outstanding, with an additional up to $10 million in Vibativ milestones. Pro forma net cash position of ~$110 million post-closing.
Risk Factors
- Shareholder vote failure — though unlikely given 41% insider support, broker non-votes count as 'against'.
- Regulatory or third-party consent delays could push closing past the August 20, 2026 outside date.
- Post-closing, Cumberland becomes a pure-play development-stage company with no commercial revenue — high execution risk on ifetroban pipeline.
- Litigation risk from shareholders challenging the deal or seeking appraisal (though no appraisal rights exist).
Market Snapshot
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFM14A Filing (Primary) | 0001104659-26-065876 |
| Document: tm2612585-2_defm14a.htm | 0001104659-26-065876 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 26, 2026
14d ago
|
DEFM14A
| $5.77 $5.77 | · 0.00% | ▼ −1.21% | $5.86 (+1.56%) |
|
Apr 23, 2026
6w ago
|
DEFA14A / 8-K
| $3.90 $4.21 | ▲ +7.95% | ▲ +6.47% | $5.86 (+50.26%) |
|
Mar 9, 2026
13w ago
|
DEFA14A
| $3.16 $3.01 | ▼ −4.75% | ▼ −3.84% | $5.86 (+85.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access